


ABSTRACT

The object of the present invention is to provide a pharmaceutical preparation for preproliferative diabetic retinopathy and/or proliferative diabetic retinopathy, that is, a prophylactic or therapeutic agent for severe diabetic retinopathy. The invention relates to a prophylactic or therapeutic agent for severe diabetic retinopathy, which comprises, as an active ingredient, a hydantoin derivative represented by the following general formula below, particularly (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide. The pharmaceutical preparation is used mainly as an agent for suppressing development into preproliferative diabetic retinopathy and/or proliferative diabetic retinopathy or as an agent for suppressing development of preproliferative diabetic retinopathy and/or proliferative diabetic retinopathy.



wherein X represents a halogen or a hydrogen atom, R^1 and R^2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R^1 and R^2 , together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.